Gouvernance Avalo Therapeutics, Inc.

AVTX

US05338F3064

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX Autres places de cotation 15:56:20 29/07/2026			Varia. 5j.	Varia. 1 janv.
19,20 ^USD	-1,66%		+8,04%	+7,98%

17/07	Avalo Therapeutics : certains actionnaires pourraient céder jusqu'à 128 189 actions	MT
26/06	Avalo Therapeutics intègre les indices Russell 2000 et Russell 3000	MT

Comité Exécutif: Avalo Therapeutics, Inc.

Dirigeant

Fonctions occupéesDepuis

Garry Neil

72 ans

Chief Executive Officer	14/02/2022
President	14/02/2022

Kathleen Cohen

Chief Tech/Sci/R&D Officer

Ashley Ivanowicz

Human Resources Officer

01/10/2025

Mittie Doyle

61 ans

Chief Tech/Sci/R&D Officer

15/07/2024

Christopher Sullivan

42 ans

Director of Finance/CFO	14/02/2022
Investor Relations Contact	-
Public Communications Contact	-

Paul Varki

53 ans

General Counsel

24/06/2024

Dino Miano

Chief Operating Officer	-
Chief Tech/Sci/R&D Officer	-

Colleen Matkowski

General Counsel

Composition du Conseil d'Administration: Avalo Therapeutics, Inc.

Administrateur

ComitésDepuis

Michael Heffernan

61 ans

Audit Committee	30/06/2019
Compensation Committee Chair	28/09/2022
Governance Committee	28/09/2022
Nominating Committee	28/09/2022

Ron Philip

Audit Committee	07/04/2025
Governance Committee	07/04/2025
Nominating Committee	07/04/2025
Compensation Committee	23/06/2026

Rita Jain

64 ans

Governance Committee	16/02/2023
Nominating Committee	16/02/2023
Audit Committee
Compensation Committee

Samantha Truex

55 ans

Compensation Committee	25/04/2024
Governance Committee Chair	25/04/2024
Nominating Committee Chair	25/04/2024

Aaron Kantoff

40 ans

Governance Committee	25/04/2024
Nominating Committee	25/04/2024
Compensation Committee Chair	25/04/2024

Garry Neil

72 ans

Audit Committee
Governance Committee Chair
Nominating Committee Chair

Gilla Kaplan

78 ans

Governance Committee
Nominating Committee

Kevin Driscoll-Lind

50 ans

Compensation Committee
Audit Committee Chair

Dernières Nominations: Avalo Therapeutics, Inc.

23/06	Avalo Therapeutics, Inc. annonce la nomination de Ron Philip à son conseil d'administration	CI
27/03	Avalo Therapeutics, Inc. annonce le départ des administrateurs Jonathan Goldman et Mitchell Chan	CI
10/02	Helus Pharma nomme Michael Cola au poste de directeur général, à compter du 10 février 2026	CI
01/10/25	Avalo Therapeutics, Inc. annonce de nouvelles nominations au sein de son conseil d'administration, effectives au 1er octobre 2025	CI
22/09/25	Avalo Therapeutics, Inc. nomme Kevin R. Lind au sein de son conseil d'administration	CI
18/06/25	Avalo Therapeutics annonce la nomination de la Dre Rita Jain au sein de son conseil d'administration	CI
26/03/25	Avalo Therapeutics nomme Michael Heffernan président du conseil d'administration	MT

Plus d'Actualités

Anciens Dirigeants et Administrateurs: Avalo Therapeutics, Inc.

Insider

Fonctions occupées

DepuisJusqu'au

Mitchell Chan

Director/Board Member	01/12/2021	02/06/2026
Independent Dir/Board Member	01/12/2021	02/06/2026

Jonathan Goldman

Director/Board Member	27/03/2024	02/06/2026
Independent Dir/Board Member	27/03/2024	02/06/2026

June Almenoff

Director/Board Member	10/11/2021	01/10/2025
Independent Dir/Board Member	10/11/2021	01/10/2025

Gunnar Magnus Modee Persson

Director/Board Member	28/08/2012	13/08/2024
Independent Dir/Board Member	28/08/2012	13/08/2024

Illya Keith Maher

Director/Board Member	15/10/2021	08/08/2022
Independent Dir/Board Member	15/10/2021	08/08/2022

Steven Boyd

Director/Board Member	15/05/2017	14/12/2021
Chairman	14/12/2021	08/08/2022
Independent Dir/Board Member	15/05/2017	08/08/2022

Joseph Miller

Director/Board Member	24/04/2020	01/06/2022
Director of Finance/CFO	12/07/2018	24/04/2020
Corporate Secretary	-	24/04/2020

Michael Cola

Director/Board Member	14/12/2021	17/02/2022
Chief Executive Officer	03/02/2020	17/02/2022
Chairman	15/06/2021	14/12/2021

Schond Greenway

Director of Finance/CFO	01/03/2021	14/02/2022
Treasurer	01/03/2021	14/02/2022

Younok Dumortier Shin

Chief Tech/Sci/R&D Officer

01/11/2020

01/02/2022

Stephen Smolinski

Corporate Officer/Principal

03/01/2022

James Harrell

Public Communications Contact	23/04/2018	08/11/2019
Corporate Officer/Principal	08/11/2019	03/01/2022
Sales & Marketing	23/04/2018	08/11/2019

Suzanne Bruhn

Director/Board Member	24/04/2020	10/11/2021
Independent Dir/Board Member	24/04/2020	10/11/2021

Phillip Gutry

Director/Board Member	01/04/2015	01/11/2021
Independent Dir/Board Member	01/04/2015	01/11/2021

Pericles Calias

Chief Tech/Sci/R&D Officer

16/07/2018

30/06/2020

Simon Pedder

Director/Board Member	24/04/2020	18/06/2020
Chairman	15/04/2019	24/04/2020
Independent Dir/Board Member	06/04/2018	15/04/2019
President	-	18/06/2020

Keith W. Schmidt

Director/Board Member	11/06/2019	18/06/2020
Independent Dir/Board Member	11/06/2019	18/06/2020

Uli Alf Hacksell

Director/Board Member	15/04/2019	18/06/2020
Chief Executive Officer	01/01/2016	14/08/2017
Chairman	01/01/2016	15/04/2019
President	01/01/2016	15/08/2017

Peter Greenleaf

Director/Board Member	28/03/2018	13/02/2020
Chief Executive Officer	28/03/2018	15/04/2019

H. Wilkins

Chief Tech/Sci/R&D Officer	01/04/2020	-
Corporate Officer/Principal	01/02/2020	01/04/2020

Stephen Thomas

Corporate Officer/Principal

01/09/2018

01/02/2020

Patrick Crutcher

Corporate Officer/Principal

01/11/2019

Matthew Phillips

Corporate Officer/Principal

22/01/2018

01/11/2019

Isaac Blech

Director/Board Member	01/03/2012	27/03/2019
Founder	31/01/2011	27/03/2019
Independent Dir/Board Member	31/01/2012	27/03/2019

Mariam Morris

Director of Finance/CFO

01/05/2015

16/07/2018

Robert E. Swedberg

Comptroller/Controller/Auditor

01/01/2013

12/07/2018

Randal Jones

Director/Board Member

17/11/2017

15/05/2018

Robert C. Moscato

Director/Board Member	17/11/2017	28/03/2018
Chief Operating Officer	17/11/2017	28/03/2018
President	17/11/2017	28/03/2018

Ronald Marcus

Chief Tech/Sci/R&D Officer	29/05/2015	17/11/2017
General Counsel	29/05/2015	17/11/2017

John Kaiser

Chief Executive Officer	14/08/2017	17/11/2017
Corporate Officer/Principal	17/10/2012	14/08/2017

Thomas Aasen

Director/Board Member	10/01/2016	16/10/2017
Independent Dir/Board Member	10/01/2016	16/10/2017

Behshad Sheldon

Director/Board Member	01/07/2014	30/09/2016
Independent Dir/Board Member	01/07/2014	30/09/2016

Blake Paterson

Director/Board Member	31/01/2011	31/12/2015
Chief Executive Officer	31/01/2011	31/12/2015
Founder	31/01/2011	31/12/2015
President	31/01/2011	31/12/2015

Mayukh Sukhatme

Director/Board Member

01/07/2014

12/08/2015

Federica O’Brien

Director of Finance/CFO	26/06/2013	01/05/2015
Corporate Secretary	26/06/2013	01/05/2015
Treasurer	26/06/2013	01/05/2015

James Vornov

Chief Tech/Sci/R&D Officer	17/10/2012	09/01/2015
General Counsel	17/10/2012	09/01/2015

Cary Sucoff

Director/Board Member

11/07/2014

John Catsimatidis

Director/Board Member

11/07/2014

Michael Barrett

Director/Board Member	01/07/2014	-
Independent Dir/Board Member	01/07/2014	-

Frank Torti

Director/Board Member	01/07/2014	-
Independent Dir/Board Member	01/07/2014	-

Karen Krumeich

Corporate Officer/Principal

01/05/2011

01/09/2013

Eugene Bauer

Director/Board Member	01/05/2011	01/01/2013
Independent Dir/Board Member	01/05/2011	01/01/2013

Bernadine Heather Fraser

Chief Operating Officer	01/03/2012	01/10/2012
Corporate Officer/Principal	01/03/2012	01/10/2012

Barbara Slusher

Founder

31/01/2011

Solomon H. Snyder

Founder

31/01/2011

Lisa Hegg

Chief Tech/Sci/R&D Officer

Garry A. Weems

Chief Tech/Sci/R&D Officer

Sol Barer

Director/Board Member	-	01/04/2015
Chairman	-	01/04/2015
Director/Board Member	03/02/2020	24/04/2020
Chairman	24/04/2020	15/06/2021
Independent Dir/Board Member	03/02/2020	15/06/2021

Seth Harrison

Director/Board Member

Hugh Huang

Corporate Officer/Principal

Maxim Jacobs

Investor Relations Contact

Dennis Liotta

Private Equity Investor

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme	12
Femme	5

Dont comité exécutif

Homme	5
Femme	3

Dont Administrateurs

Homme	7
Femme	1

Avalo Therapeutics, Inc. est une société de biotechnologie au stade clinique qui se concentre sur le traitement de la dysrégulation immunitaire. L'actif principal de la société est l'AVTX-009, un AcM anti-IL-1β, qui cible les maladies inflammatoires. Son pipeline comprend également le quisovalimab (AcM anti-LIGHT) et l'AVTX-008 (protéine de fusion agoniste BTLA). AVTX-009 est un anticorps monoclonal humanisé (IgG4) qui se lie à l'interleukine-1β (IL-1β) avec une grande affinité et neutralise son activité. L'IL-1β joue un rôle central dans le processus inflammatoire. Le Quisovalimab est un anticorps monoclonal (mAb) entièrement humain, dirigé contre LIGHT humain (Lymphotoxin-like, exhibits Inducible expression, and competes with Herpes Virus Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes). AVTX-008 est une protéine de fusion agoniste de l'atténuateur de lymphocytes B et T (BTLA) entièrement humaine. AVTX-008 se différencie par sa liaison spécifique à BTLA, sans liaison à LIGHT ou CD160.

Employés

Secteur

Recherche biotechnologique et médicale

Plus d'informations sur la société